



# Cybin Enters into Collaboration Agreement with Greenbrook TMS to Establish Mental Health Centers of Excellence

7.6.21

TORONTO,  
CANADA

–

July,

6,

2021

–

[Cybin](#)

[Inc.](#)

[\(NEO:CYBN\)](#)

[Our Work](#)[Investors](#)[About Us](#)

or  
the  
“**Company**”),  
a  
biotechnology  
company  
focused  
on  
progressing  
psychedelic  
therapeutics,  
today  
announced  
that  
it  
has  
entered  
into  
an  
exclusive  
research  
and  
development  
collaboration  
agreement

[Our Work](#)[Investors](#)[About Us](#)

**Agreement”)**

with

TMS

NeuroHealth

Centers

Inc.,

a

wholly-

owned

subsidiary

of

Greenbrook

TMS

Inc.

(TSX:GTMS)

(NASDAQ:GBNH)

(“**Greenbrook**”).

Greenbrook

operates

129

outpatient

mental

health

service

centers



[Our Work](#)

[Investors](#)

[About Us](#)

United States. Pursuant to the Collaboration Agreement, Cybin and Greenbrook will work together to establish Mental Health Centers of Excellence for the purpose of facilitating



Our Work

Investors

About Us

development  
of  
innovative  
psychedelic  
compound-  
based  
therapeutics  
for  
patients  
suffering  
from  
depression.

Cybin  
and  
Greenbrook  
are  
both  
on  
a  
mission  
to  
assist  
individuals  
suffering

[Our Work](#)[Investors](#)[About Us](#)

and  
the  
synergistic  
opportunity  
to  
combine  
forces  
was  
evident.

Greenbrook's  
affiliated  
physicians  
have  
treated  
over  
17,000  
patients  
suffering  
from  
Major  
Depressive  
Disorder  
and  
other  
mental



[Our Work](#)

[Investors](#)

[About Us](#)

in  
the  
United  
States,  
while  
Cybin  
is  
a  
leader  
in  
the  
research  
and  
development  
of  
novel  
compounds  
and  
delivery  
mechanisms  
and  
is  
building  
the  
foundation



[Our Work](#)

[Investors](#)

[About Us](#)

it believes will become the next generation of commercially viable psychedelic therapeutics for the treatment of mental health disorders, including depression.

The network of





Our Work

Investors

About Us

health  
service  
centers  
that  
Greenbrook  
has  
built  
over  
the  
years  
will  
provide  
Cybin  
a  
leading  
market  
advantage  
to  
resources  
and  
patients  
that  
can  
assist  
in



Our Work

Investors

About Us

study  
programs  
in  
the  
US  
as  
patient  
access  
regularly  
becomes  
a  
hurdle  
in  
this  
specific  
process.

Pursuant  
to  
the  
Collaboration  
Agreement,  
both  
Cybin  
and



Our Work

Investors

About Us

collaborate  
to  
develop  
one  
or  
more  
Centers  
of  
Excellence  
for  
the  
purpose  
of  
facilitating  
research  
and  
development  
of  
innovative  
psychedelic  
compound-  
based  
therapeutics  
for  
patients



[Our Work](#)

[Investors](#)

[About Us](#)

depression.

Specific

projects

to

be

pursued

at

the

Center(s)

of

Excellence,

will

look

at:

-



Our Work

Investors

About Us

•

•



[Our Work](#)

[Investors](#)

[About Us](#)

that  
the  
formation  
of  
Center(s)  
of  
Excellence  
and  
the  
potential  
to  
leverage  
one  
of  
the  
largest  
outpatient  
mental  
health  
service  
center  
footprints  
in  
the  
US



Our Work

Investors

About Us

FDA  
approved  
psychedelic  
medicines  
will  
add  
near-  
term  
and  
long-  
term  
value  
to  
patients  
and  
stakeholders  
alike.

Doug  
Drysdale,  
Cybin's  
CEO,  
added,  
"We  
are



[Our Work](#)

[Investors](#)

[About Us](#)

and  
excited  
to  
be  
working  
with  
the  
world-  
class  
team  
at  
Greenbrook  
TMS  
to  
establish  
these  
important  
Centers  
of  
Excellence.  
This  
opportunity  
to  
combine  
our





[Our Work](#)

[Investors](#)

[About Us](#)

and  
clinical  
knowledge  
of  
psychedelic  
therapeutics  
with  
Greenbrook's  
deep  
experience  
in  
patient  
care  
and  
delivery  
is  
unparalleled  
and  
serves  
as  
a  
major  
step  
toward  
establishing



[Our Work](#)

[Investors](#)

[About Us](#)

distribution  
network  
for  
future  
psychedelic  
therapies.”

## **About Greenbrook**

Operating  
through  
129  
company-  
operated  
treatment  
centers,  
Greenbrook  
is  
a  
leading  
provider  
of  
Transcranial  
Magnetic



[Our Work](#)

[Investors](#)

[About Us](#)

therapy,  
an  
FDA-  
cleared,  
non-  
invasive  
therapy  
for  
the  
treatment  
of  
Major  
Depressive  
Disorder  
and  
other  
mental  
health  
disorders,  
in  
the  
United  
States.  
TMS  
therapy

[Our Work](#)[Investors](#)[About Us](#)

electromagnetic

stimulation

to

specific

brain

regions

known

to

be

directly

associated

with

mood

regulation.

Greenbrook

has

provided

more

than

620,000

TMS

treatments

to

over

17,000



[Our Work](#)

[Investors](#)

[About Us](#)

with  
depression.

[www.greenbrooktms.com](http://www.greenbrooktms.com)

## About

### Cybin

Cybin  
is  
a  
leading  
biotechnology  
company  
focused  
on  
progressing  
psychedelic  
therapeutics  
by  
utilizing  
proprietary  
drug  
discovery  
platforms,  
innovative



[Our Work](#)

[Investors](#)

[About Us](#)

systems,  
novel  
formulation  
approaches  
and  
treatment  
regimens  
for  
psychiatric  
disorders.

**Cautionary  
Notes  
and  
Forward-  
Looking  
Statements**

Certain  
statements  
in  
this  
news  
release  
related



[Our Work](#)

[Investors](#)

[About Us](#)

Company

are

forward-

looking

statements

and

are

prospective

in

nature.

Forward-

looking

statements

are

not

based

on

historical

facts,

but

rather

on

current

expectations

and



Our Work

Investors

About Us

future  
events  
and  
are  
therefore  
subject  
to  
risks  
and  
uncertainties  
which  
could  
cause  
actual  
results  
to  
differ  
materially  
from  
the  
future  
results  
expressed  
or  
implied





Our Work

Investors

About Us

forward-  
looking  
statements.

These  
statements  
generally

can

be

identified

by

the

use

of

forward-

looking

words

such

as

“may”,

“should”,

“could”,

“intend”,

“estimate”,

“plan”,

“anticipate”,



[Our Work](#)

[Investors](#)

[About Us](#)

or  
“continue”,  
or  
the  
negative  
thereof  
or  
similar  
variations.  
Forward-  
looking  
statements  
in  
this  
news  
release  
include  
statements  
regarding  
enhanced  
liquidity,  
the  
value  
of  
additional



[Our Work](#)

[Investors](#)

[About Us](#)

exposure,  
access  
to  
institutional  
and  
retail  
investors,  
the  
Company's  
new  
strategic  
brand  
messaging  
campaign,  
and  
psychedelic  
drug  
development  
programs  
to  
potentially  
treat  
mental  
health  
disorders.



Our Work

Investors

About Us

numerous risks and uncertainties that could cause actual results and Cybin's plans and objectives to differ materially from those expressed in the forward-looking information.



Our Work

Investors

About Us

and  
future  
events  
could  
differ  
materially  
from  
those  
anticipated  
in  
such  
information.

These  
and  
all  
subsequent  
written  
and  
oral  
forward-  
looking  
information  
are  
based  
on



[Our Work](#)

[Investors](#)

[About Us](#)

opinions  
of  
management  
on  
the  
dates  
they  
are  
made  
and  
are  
expressly  
qualified  
in  
their  
entirety  
by  
this  
notice.  
Except  
as  
required  
by  
law,  
the



Our Work

Investors

About Us

not  
intend  
to  
update  
these  
forward-  
looking  
statements.

Cybin  
makes  
no  
medical,  
treatment  
or  
health  
benefit  
claims  
about  
Cybin's  
proposed  
products.  
The  
U.S.  
Food



[Our Work](#)

[Investors](#)

[About Us](#)

Administration,

Health

Canada

or

other

similar

regulatory

authorities

have

not

evaluated

claims

regarding

psilocybin,

psychedelic

tryptamine,

tryptamine

derivatives

or

other

psychedelic

compounds

or

nutraceutical

products.



[Our Work](#)[Investors](#)[About Us](#)

of  
such  
products  
have  
not  
been  
confirmed  
by  
approved  
research.  
There  
is  
no  
assurance  
that  
the  
use  
of  
psilocybin,  
psychedelic  
tryptamine,  
tryptamine  
derivatives  
or  
other



[Our Work](#)

[Investors](#)

[About Us](#)

or  
nutraceuticals  
can  
diagnose,  
treat,  
cure  
or  
prevent  
any  
disease  
or  
condition.  
Vigorous  
scientific  
research  
and  
clinical  
trials  
are  
needed.  
Cybin  
has  
not  
conducted  
clinical



[Our Work](#)

[Investors](#)

[About Us](#)

the  
use  
of  
its  
proposed  
products.  
Any  
references  
to  
quality,  
consistency,  
efficacy  
and  
safety  
of  
potential  
products  
do  
not  
imply  
that  
Cybin  
verified  
such  
in



[Our Work](#)

[Investors](#)

[About Us](#)

or  
that  
Cybin  
will  
complete  
such  
trials.  
If  
Cybin  
cannot  
obtain  
the  
approvals  
or  
research  
necessary  
to  
commercialize  
its  
business,  
it  
may  
have  
a  
material



Our Work

Investors

About Us

on  
Cybin's  
performance  
and  
operations.

*The  
NEO  
Exchange  
has  
neither  
approved  
nor  
disapproved  
the  
contents  
of  
this  
news  
release  
and  
is  
not  
responsible*



Our Work

Investors

About Us

*adequacy  
and  
accuracy  
of  
the  
contents  
herein.*

**Investor**

**Contacts:**

Tim

Regan/Scott

Eckstein

KCSA

Strategic

Communications

[Cybin@kcsa.com](mailto:Cybin@kcsa.com)

Lisa

M.

Wilson

In-

Site



[Our Work](#)

[Investors](#)

[About Us](#)

[lwilson@insitecony.com](mailto:lwilson@insitecony.com)

## Media

### Contacts:

John

Kanakis

Cybin

Inc.

[John@cybin.com](mailto:John@cybin.com)

[PREVIOUS POST](#)

[NEXT POST](#)



Our Work

Investors

About Us

5600-100 King St W, Toronto ON  
M5X 1C9  
Investor Contact: [ir@cybin.com](mailto:ir@cybin.com)  
General Contact:  
[info@cybin.com](mailto:info@cybin.com)

[The Science](#)

[Cybin x Kernel](#)

[Financials](#)

[Corporate Governance](#)

[Downloads](#)

[Team](#)

[News](#)

[Join Us](#)

[Contact](#)

Copyright Cybin Corp. © 2021 . All rights reserved.

[Privacy Policy](#)